Repeat Dosing of Psilocybin in Migraine Headache

Conditions

Headaches

Phase I

Volunteers
Health Professionals

What is the purpose of this trial?

In seeking to understand the capacity for psilocybin to reduce migraine headache burden, this study will investigate single and repeated dosing of psilocybin up to two doses. In seeking to identify an underlying mechanism in psilocybin's effects, neuroinflammatory markers for migraine headache will be measured.

Ages
21 years - 65 years
Gender
Both

Find out more about who can participate in this trial

Trial with
Wallace Research Foundation
Start Date
01/01/2021
End Date
07/15/2022

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Emmanuelle Schindler, MD, PhD
Assistant Professor; Medical Director, Headache Center of Excellence

Sub-Investigator

Deepak Cyril Dsouza, MBBS, MD

Last Updated
04/05/2022
Study HIC
#2000026974